Phenotypic Assessment and the Discovery of Topiramate

ACS Medicinal Chemistry Letters

Volumn 7, Issue 7, 2016, Pages 662-665

  Maryanoff, Bruce E ^a,b  

^a BARUCH S BLUMBERG INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

anticonvulsant; Drug discovery; epilepsy; phenotype; topiramate

Indexed keywords

TOPIRAMATE;

ARTICLE; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; EPILEPSY; MIGRAINE; PHENOTYPE; PRIORITY JOURNAL;

EID: 84978701456     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00176     Document Type: Article

References (40)

1. Lefkowitz, R. J.; Haber, E.; O'Hara, D. Identification of the cardiac beta-adrenergic receptor protein: solubilization and purification by affinity chromatography Proc. Natl. Acad. Sci. U. S. A. 1972, 69, 2828-2832 10.1073/pnas.69.10.2828
2. Pert, C. B.; Snyder, S. H. Opiate receptor: demonstration in nervous tissue Science 1973, 179 (4077) 1011-1014 10.1126/science.179.4077.1011
3. Pert, C. B.; Snyder, S. H. Properties of opiate-receptor binding in rat brain Proc. Natl. Acad. Sci. U. S. A. 1973, 70, 2243-2247 10.1073/pnas.70.8.2243
4. Pert, C. B.; Snyder, S. H. Opiate receptor binding of agonists and antagonists affected differentially by sodium Mol. Pharmacol. 1974, 10, 868-879
5. Simon, E. J.; Hiller, J. M.; Groth, J.; Edelman, I. Further properties of stereospecific opiate binding sites in rat brain: on the nature of the sodium effect J. Pharmacol. Exp. Ther. 1975, 192, 531-537
6. Priest, B. T.; Erdemli, G. Phenotypic screening in the 21st century Front. Pharmacol. 2014, 5, 1-2 10.3389/fphar.2014.00264
7. Zheng, W.; Thorne, N.; McKew, J. C. Phenotypic screens as a renewed approach for drug discovery Drug Discovery Today 2013, 18, 1067-1073 10.1016/j.drudis.2013.07.001
8. Prior, M.; Chiruta, C.; Currais, A.; Goldberg, J.; Ramsey, J.; Dargusch, R.; Maher, P. A.; Schubert, D. Back to the future with phenotypic screening ACS Chem. Neurosci. 2014, 5, 503-513 10.1021/cn500051h
9. Swinney, D. C.; Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discovery 2011, 10, 507-519 10.1038/nrd3480
10. Maslow, A. H. The Psychology of Science; Harper & Row: New York, 1966; p 15 [qv. https://en.wikipedia.org/wiki/Abraham-Maslow#Maslow.27s-hammer; accessed in March 2016, ].
11. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1, 493-502 10.1038/nrd839
12. Druker, B. J.; Lydon, N. B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia J. Clin. Invest. 2000, 105, 3-7 10.1172/JCI9083
13. Peters, J.-U. Polypharmacology-foe or friend? J. Med. Chem. 2013, 56, 8955-8971 10.1021/jm400856t
14. Anighoro, A.; Bajorath, J.; Rastelli, G. Poly-pharmacology: challenges and opportunities in drug discovery J. Med. Chem. 2014, 57, 7874-7887 10.1021/jm5006463
15. The inhibitors target the ATP-binding site of protein kinases, 518 of which exist in the human kinome (see: https://en.wikipedia.org/wiki/kinome; accessed in March 2016).
16. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discovery 2004, 3, 673-683 10.1038/nrd1468
17. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discovery 2004, 3, 353-359 10.1038/nrd1346
18. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 2008, 4, 682-690 10.1038/nchembio.118
19. Jalencas, X.; Mestres, J. On the origins of drug polypharmacology MedChemComm 2013, 4, 80-87 10.1039/C2MD20242E
20. Lukaszewicz, A. I.; McMillan, M. K.; Kahn, M. Small molecules and stem cells. Potency and lineage commitment: the new quest for the fountain of youth J. Med. Chem. 2010, 53, 3439-3453 10.1021/jm901361d
21. Viswanathan, P.; Gaskell, T.; Moens, N.; Culley, O. J.; Hansen, D.; Gervasio, M. K. R.; Yeap, Y. J.; Danovi, D. Human pluripotent stem cells on artificial microenviroments: a high content perspective Front. Pharmacol. 2014, 5 (150) 1-14 10.3389/fphar.2014.00150
22. Gonzalez-Munoz, A. L.; Minter, R. R.; Rust, S. J. Phenotypic screening: the future of antibody discovery Drug Discovery Today 2016, 21, 150-156 10.1016/j.drudis.2015.09.014
23. Vincent, F.; Loria, P.; Pregel, M.; Stanton, R.; Kitching, L.; Nocka, K.; Doyannas, R.; Steppan, C.; Gilbert, A.; Schroeter, T.; Peakman, M.-C. Developing predictive assays: the phenotypic screening ″rule of 3″ Sci. Transl. Med. 2015, 7 (293) 1-5 10.1126/scitranslmed.aab1201
24. Kang, J.; Hsu, C.-H.; Wu, Q.; Liu, S.; Coster, A. D.; Posner, B. A.; Altschuler, S. J.; Wu, L. F. Improving drug discovery with high-content phenotypic screens by systematic selection of reported cell lines Nat. Biotechnol. 2016, 34, 70-77 10.1038/nbt.3419
25. Heath, J. R.; Ribas, A.; Mischel, P. S. Single-cell analysis tools for drug discovery and development Nat. Rev. Drug Discovery 2016, 15, 204-216 10.1038/nrd.2015.16
26. Zhang, J. D.; Kung, E.; Boess, F.; Certa, U.; Ebeling, M. Pathway reporter genes define molecular phenotypes of human cells BMC Genomics 2015, 16, 1-10 10.1186/s12864-015-1532-2
27. Palacino, J.; Swalley, S. E.; Song, C.; Cheung, A. K.; Shu, L.; Zhang, X.; Van Hoosear, M.; Shin, Y.; Chin, D. N.; Keller, C. G. et al. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice Nat. Chem. Biol. 2015, 11, 511-517 10.1038/nchembio.1837
28. Rihel, J.; Prober, D. A.; Arvanites, A.; Lam, K.; Zimmerman, S.; Jang, S.; Haggarty, S. J.; Kokel, D.; Rubin, L. L.; Peterson, R. T.; Schier, A. F. Zebrafish behavioral profiling links to biological targets and rest/wake regulation Science 2010, 327, 348-351 10.1126/science.1183090
29. Bruni, G.; Lakhani, P.; Kokel, D. Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish Front. Pharmacol. 2014, 5 (153) 1-7 10.3389/fphar.2014.00153
30. McCarroll, M. N.; Gendelev, L.; Keiser, M. J.; Kokel, D. Leveraging large-scale behavioral profiling in zebrafish to explore neuroactive pharmacology ACS Chem. Biol. 2016, 11, 842-849 10.1021/acschembio.5b00800
31. Schirle, M.; Jenkins, J. L. Identifying compound efficacy targets in phenotypic drug discovery Drug Discovery Today 2016, 21, 82-89 10.1016/j.drudis.2015.08.001
32. Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical proteomics Nat. Chem. Biol. 2009, 5, 616-624 10.1038/nchembio.216
33. Kotz, J. Phenotypic screening, take two SciBX: Science-Business eXchange 2012, 5 (15) 1-3 10.1038/scibx.2012.380
34. Maryanoff, B. E. Pharmaceutical "gold" from neurostabilizing agents: topiramate and successor molecules J. Med. Chem. 2009, 52, 3431-3440 10.1021/jm900141j
35. The 2008 Johnson & Johnson Annual Report (http://www.investor.jnj.com/annual-reports.cfm, p 23; accessed in April 2016).
36. Shank, R. P.; Gardocki, J. F.; Streeter, A. J.; Maryanoff, B. E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action Epilepsia 2000, 41, S3-S9 10.1111/j.1528-1157.2000.tb02163.x
37. Porter, R. J.; Dhir, A.; Macdonald, R. L.; Rogawski, M. A. Mechanisms of action of antiseizure drugs Handbook of Clinical Neurology, Epilepsy Part II 2012, 108, 663-681 10.1016/B978-0-444-52899-5.00021-6
38. Zamponi, G. W. Targeting voltage-gated calcium channels in neurological and psychiatric diseases Nat. Rev. Drug Discovery 2016, 15, 19-34 10.1038/nrd.2015.5
39. Maryanoff, B. E.; McComsey, D. F.; Costanzo, M. J.; Hochman, C.; Smith-Swintosky, V.; Shank, R. P. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform J. Med. Chem. 2005, 48, 1941-1947 10.1021/jm040124c
40. Landmark, C. J. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy CNS Drugs 2008, 22, 27-47 10.2165/00023210-200822010-00003